摘要
在难治性癫痫尤其是Dravet综合征和Lennox-Gastaut综合征的治疗方面,大麻中的抗惊厥成分——大麻二酚显示出良好的疗效和安全性。然而,其作用机制以及与其他药物之间的相互作用尚不明确,对于已经应用多种抗癫痫药物的难治性癫痫患者,大麻二酚的应用使其治疗更见曙光但也更加复杂化。本文将重点综述大麻二酚的相关作用机制研究及其在难治性癫痫治疗中的临床研究进展。
In the treatment of refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome, cannabidiol, an anticonvulsant component of marijuana, has shown significant efficacy and safety. However, its mechanism of action and interaction with other drugs are still unclear. For refractory patients who have been treated with a variety of antiepileptic drugs, cannabidiol makes their treatment more promising but also more complicated. This review focuses on the mechanism of cannabidiol and its clinical research progress in the treatment of refractory epilepsy.
作者
李臻
王雁
Kwan Patrick
Li Zhen;Wang Yan(Department of Neurology,the Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Neurology,Royal Melbourne Hospital,Parkville 3050,Australia)
出处
《中华神经科杂志》
CAS
CSCD
北大核心
2019年第7期586-591,共6页
Chinese Journal of Neurology
关键词
癫痫
大麻
大麻二酚
抗癫痫药物
Epilepsy
Marijuana
Cannabidiol
Antiepileptic drugs
